Abstract
This commentary discusses the retrospective study by Weight and colleagues, which evaluated the practice patterns of US physicians using androgen deprivation therapy (either medical castration with luteinizing hormone-releasing hormone [LHRH] agonists or surgical castration by orchiectomy) for the treatment of Medicare patients with prostate cancer during 2001–2005. In 2003, the enactment of the Medicare Modernization Act (MMA), which lowered reimbursement for LHRH analog administration, was introduced. The authors found that LHRH agonist use increased in 2001–2003, and decreased in 2004 and 2005, while surgical castration rates increased. The authors speculated that the treatment decisions for androgen deprivation therapy were financially influenced. Although this study highlights the possible influence that reimbursement levels might have in the decision to prescribe androgen deprivation therapy, the study has several limitations, and the conclusion that financial incentives were solely responsible for the observed decrease in LHRH agonist use can not be made.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Huggins C and Hodges CV (1941) Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–307
Weight CJ et al. (2008) Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer 112: 2195–2201
Maillefert JF et al. (1994) Gonadotrophin-releasing hormone agonists induce osteoporosis. Br J Rheumatol 33: 1199–2000
Keating NL et al. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456
D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827
Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781–1788
Bolla M et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300
Soloway MS et al. (2002) Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167: 112–116
Lu-Yao GL et al. (2008) Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300: 173–181
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Katz, M., Andriole, G. Are changes in US practices for androgen deprivation therapy financially motivated?. Nat Rev Urol 5, 534–535 (2008). https://doi.org/10.1038/ncpuro1201
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1201